Here's what experiments TRISH is launching aboard Axiom Space's next mission. Photo via NASA

Houston's Translational Research Institute for Space Health, or TRISH, will launch six more experiments into space this spring aboard Axiom Space's Ax-2 mission, the organization announced this week.

The biomedical research conducted through TRISH, in consortium with CalTeach and MIT, will look into how space travel impacts everything from motion sickness to memory over the course of the mission's 10-day stint on the International Space Station.

The crew will consist of four astronauts: Commander Peggy Whitson (previously with NASA), Pilot John Shoffner and Mission Specialists Ali AlQarni and Rayyanah Barnawi. It's a historic team, bringing the first female private space crew commander and the first Saudi astronauts to the ISS.

“Insights gathered from this work improve our understanding of how the human body and mind respond to spaceflight, helping us to prepare future astronauts to remain safe and healthy during longer-duration missions," Dr. Dorit Donoviel, TRISH executive director and professor in the Center for Space Medicine at Baylor College of Medicine, says in a statement.

The six projects onboard the mission have been developed by researchers within TRISH as well as the University of Pennsylvania Perelman School of Medicine, Johns Hopkins University and Baylor College of Medicine. They aim to assess the following:

  • Spaceflight participants’ performance in memory, abstraction, spatial orientation, emotion recognition, risk decision making and sustained attention before and after the mission -Astronauts’ inner ears and eyes' response to motion before and after space travel and how this relates to motion sickness and nausea during launch and landing
  • The effects of spaceflight on the human body at the genomic level
  • Changes to the eyes and brain during spaceflight
  • Astronaut's sleep, personality, health history, team dynamics and immune-related symptoms
  • Sensorimotor abilities and changes in space and how this can impact astronauts' ability to stand, balance and have full body control on the moon

Some of this information will become part of TRISH’s Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program, which aims to boost human health on commercial space flights through its database. The program launched in 2021.

Ax-2 is Axiom's second all-private astronaut mission to the ISS and will launch out of NASA’s Kennedy Space Center in Florida aboard a SpaceX's Dragon spacecraft. Axiom was first established in 2016 with the goal of building the world's first commercial space station.

TRISH is also slated to launch nine experiments on board SpaceX's Polaris Dawn mission, which is now expected to launch this summer. The research aboard Polaris Dawn is intended to complement research supported by TRISH on the Inspiration4 all-civilian mission to orbit, which was also operated by SpaceX in 2021.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.